Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | CD44 | P16070 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10321000 | 0.87 | MAOB (0.46) | TSHRMAOBPNMTCD44HTR2C | |
| SCHEMBL37705 | 0.73 | PNMT (0.39) | MAOBPNMTCD44HTR2CALOX15 | |
| SCHEMBL155050 | 0.71 | MAPT (0.46) | TSHRMAOBHTR2CMAPTNOS3 | |
| SCHEMBL10321111 | 0.70 | HTR2C (0.52) | TSHRMAOBPNMTCD44HTR2C | |
| SCHEMBL8355 | 0.68 | TSHR (1.00) | TSHRMAOBPNMTCD44HTR2C | |
| SCHEMBL451157 | 0.68 | TSHR (0.86) | TSHRMAOBPNMTCD44HTR2C | |
| SCHEMBL9662 | 0.68 | — | — | |
| SCHEMBL11606739 | 0.68 | TSHR (1.00) | TSHRMAOBPNMTCD44HTR2C | |
| SCHEMBL11645158 | 0.68 | TSHR (1.00) | TSHRMAOBPNMTCD44HTR2C | |
| SCHEMBL385555 | 0.68 | TSHR (1.00) | TSHRMAOBPNMTCD44HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303567-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP | 2013-11-14 | — | — | US | claimed |
| US-20130303567-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP | 2013-11-14 | — | — | US | disclosed |
| US-8513433-B2 | Small molecule inhibitors of PARP activity | ANGION BIOMEDICA CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120184533-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303567-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | PARP1, PARP11, PARP15 | TSHR 4709/4885MAOB 643/4885PNMT 1174/4885 |
| US-20120184533-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | PARP1, PARP11, PARP15 | TSHR 4709/4885MAOB 643/4885PNMT 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.